Bromelain (Mucpharm)

菠萝蛋白酶（Mucpharm）

Report date: 2024/11/21 20:00:04

Base Information

Drug NameBromelain (Mucpharm)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Enzyme > Non-recombinant enzyme
Mechanisms of ActionPeptide hydrolase replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, AdultPeritoneal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMucpharm Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMucpharm Pty Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Distress Syndrome, Adult
Inactive IndicationsPeritoneal NeoplasmsPseudomyxoma PeritoneiAdenocarcinoma, Mucinous +[4] 

Other Information

ATC CodeN/A
Related LinksN/A